Thomas Novak
LinkedIn Copy
Hey Thomas — similar PE background, been deep in lower middle-market origination thinking lately. Would be good to connect.
Hey Thomas, see we share a similar PE path, though I was in London doing growth equity not building a PE firm in New England. most funds at this stage have stacked up a pretty solid toolkit — PitchBook, a CRM like Affinity or DealCloud, maybe Grata, sourcing consultants, the works. but the proprietary pipeline rarely reflects the size of the stack. none of it connects systematically, so the firm's thesis and network intelligence don't feed into each other — origination stays inconsistent instead of compounding. keen to know if Oakhurst sees the same thing, or if you've cracked something better? — Russ
Hey Thomas, see we share a similar PE path, though I was in London doing growth equity not building a PE firm in New England. most funds at this stage have stacked up a pretty solid toolkit — PitchBook, a CRM like Affinity or DealCloud, maybe Grata, sourcing consultants, the works. but the proprietary pipeline rarely reflects the size of the stack. none of it connects systematically, so the firm's thesis and network intelligence don't feed into each other — origination stays inconsistent instead of compounding. do you disagree? — Russ
hey Thomas — this kept rattling around. when I was doing growth equity we had every subscription going — PitchBook, CRM, enrichment tools, the lot — and I still spent half my time manually pulling origination together across all of it. always wondered if that was just us being disorganised or if it's genuinely universal. did you ever run into that at Oakhurst, or was it just us? — Russ
hey Thomas — appreciate the connect either way. I'm in and around lower middle-market origination all day — if you ever want to swap notes on what's working, I'm easy to find. — Russ
Email Copy
No email copy generated yet.
Prospect Research
## PROSPECT INFORMATION: Name: Thomas Novak Title: Managing Member Fund: Oakhurst Capital Partners Background: Thomas Novak is a highly experienced CPA and business leader currently serving as the Co-Founder, President, and Treasurer of SeqCoast Genomics, a biotechnology firm based in New Hampshire. He also holds the role of Managing Member at Oakhurst Capital Partners. His current focus is on scaling SeqCoast Genomics, which provides specialized Nanopore and Illumina sequencing and bioanalytics services. He is particularly focused on healthcare-associated infection (HAI) surveillance through the company's SWIFT Analytics™ platform and ensuring high-quality genomic data retrieval via AWS cloud integration. His background is characterized by significant financial leadership roles across various industries. Previously, he was part of the leadership team at The BBI Group and served as VP of Finance and Treasurer for Auto Europe Car Rental. He spent several years at IDEXX Laboratories in regional CFO and treasury management roles, including serving as a Board Director for a China Joint Venture. Earlier in his career, he held financial management positions at United Technologies (working in London and Seoul) and Deloitte. He holds a BA in Accounting from Michigan State University and has been a licensed CPA since 1987. Key skills include strategic financial planning, treasury management, mergers and acquisitions, risk management, and scaling biotechnology startups. He is also an active mentor within the Maine Mentor Network and SCORE. Relevant LinkedIn Posts: August 21, 2025: Thomas reshared a post from Michelle Clay regarding the University of Maryland's Molecular and Cellular Biology Department Retreat. He added: "Stop by to chat about your research goals and learn more about how we can help. Help me out and take some taffy and a notebook - I do NOT want to lug it on my return flight! 😮💨" September 4, 2024: He promoted his team’s presence at the ASCP 2024 conference and wrote: "Michelle Clay, PhD and Thomas Novak, CPA are pleased to be presenting SWIFT Analytics™ alongside our collaborators at Theiagen Genomics - Joel Sevinsky and Gregory Legacki. Find us at Booth 618! SWIFT Analytics™ (Surveillance and Whole-Genome InFection Tracking) uses next generation sequencing and customized reporting to provide fast, understandable insights to your infection prevention team." January 27, 2024: Thomas highlighted the company's technical capabilities, stating: "Ensure the integrity of your plasmids and optimize your research workflow with SeqCoast Genomics! SeqCoast is an Oxford Nanopore Service Certified laboratory! SeqCoast is proud to integrate Oxford Nanopore Technologies into our services, providing researchers with robust and accurate plasmid sequencing." June 21, 2023: He reshared news regarding a successful genomic submission: "We submitted a fully annotated complete genome of Escherichia coli -TG1 to GenBank. The following are the accession numbers for the chromosome and the F plasmid, respectively - CP128218 & CP128219." Fund details: - Description: Oakhurst Capital Partners is a private equity firm comprised of a network of operating executives with broad leadership experience and functional experts with deep skills. All are passionate for building strong, sustainable, and profitable businesses that will help grow the New England economy. • We add value through active participation in management, supported by the necessary capital and resources to achieve growth. • We are customer-centric in developing goals, systems, and organizations. • We invest in people to develop high performing teams, who are accountable, innovative, collaborative, flexible, and who remain focused on their purpose to provide exceptional value to customers. - Website: https://www.oakhurstcapital.co - Location: Cape Elizabeth, Maine, United States - Lead qualification: Research: - Query: =Oakhurst Capital Partners Thomas Novak recent investments fund thesis - Answer: Thomas Novak is a partner at Oakhurst Capital Partners, focusing on private equity investments in lower middle-market businesses. The firm targets sectors like biotechnology, information technology, and specialty manufacturing. Oakhurst Capital Partners emphasizes operational improvements and long-term value creation.